The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income | 1,157 |
| Depreciation and amortization | 1,011 |
| Stock-based compensation expense | 76 |
| Amortization of deferred financing costs | 59 |
| Embedded derivative on debt | 41 |
| Credit losses | 54 |
| Unrealized foreign exchange loss (gain), net | -68 |
| Amortization of inventory step-up | 0 |
| Loss on extinguishment of debt | -58 |
| Non-cash lease expense | 72 |
| Other non-cash adjustments | -13 |
| Trade accounts receivable | 355 |
| Inventories | 264 |
| Other assets | 126 |
| Accounts payable | 73 |
| Accrued expenses and other current liabilities | -92 |
| Other liabilities | -19 |
| Net cash provided by operating activities | 1,744 |
| Purchases of property and equipment, net | 447 |
| Acquisitions of businesses, net of cash acquired | -6 |
| Cash paid for asset acquisitions | 33 |
| Other investing activities | 0 |
| Net cash used in investing activities | -474 |
| Proceeds from issuance of class a common stock in initial public offering, net of underwriting discounts and commissions | 7,048 |
| Purchase of class a common stock and redemptions of common units from pre-ipo owners | 1,970 |
| Payment for offering costs | 36 |
| Proceeds from long-term borrowings | 7,569 |
| Repayment for long-term borrowings | 11,661 |
| Repayments under lines of credit | 179 |
| Proceeds from lines of credit | 179 |
| Payment for debt issuance cost | 0 |
| Payment towards class b unit repurchases | 33 |
| Distributions to partners | 518 |
| Net cash provided by (used in) financing activities | 399 |
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | 23 |
| Net change in cash and cash equivalents and restricted cash | 1,692 |
| Cash, cash equivalents and restricted cash, beginning of year | 250 |
| Cash, cash equivalents and restricted cash, end of year | 1,942 |
Medline Inc. (MDLN)
Medline Inc. (MDLN)